Skill-Stack
9-12 Days

PSUR & DSUR Reporting Certification

Complete draft of Periodic Safety Update Reports (PSUR/DSUR) using automated line listings.

PSUR & DSUR Reporting Certification
Program Tuition

₹8,999

What's Included

  • Standard Enrollment Access
  • Digital Verified Certificate
  • Community Peer Review
  • Industry-Grade Simulation
  • Expert-Level Simulation
  • Elite Certification
  • Complex Architecture
  • Advisor Artifact Review
Rating
4.8
Duration
9-12 Days
Exp
+1,200 XP
Lang
English
Badge
Certified

What is PSUR & DSUR Reporting Certification?

PSUR & DSUR Reporting Certification is a simulation-based program that trains pharmacovigilance professionals to plan, compile, draft, quality-check, and submit Periodic Safety Update Reports and Development Safety Update Reports — the two primary aggregate safety reporting formats required by regulatory authorities globally. Built on ICH E2C(R2) and ICH E2F guidelines and anchored in real-world data aggregation workflows, this program covers the complete aggregate reporting lifecycle: pulling and organising cumulative safety data, building line listings and summary tabulations, applying AI-assisted drafting tools, conducting benefit-risk evaluations, managing PSUR and DSUR quality reviews, handling regulatory queries, and submitting to the FDA, EMA, and other major agencies on mandated timelines. It is part of the Professional track at Zane ProEd Academy and is executed entirely inside ΩMEGA, Zane's hybrid clinical simulation engine. Aggregate reporting is where individual case data becomes regulatory evidence — this program trains you to make that translation at industry standard.

THE ACADEMY OUTPUT

Your Deliverable: The PSUR/DSUR Reporting Portfolio Compile cumulative adverse event data across a simulated product safety history. Build line listings and summary tabulations. Draft a complete PSUR and DSUR section by section. Apply AI-assisted drafting tools and validate their output. Run quality checks. Handle a simulated regulatory query. Submit to regulatory standard with full documentation of methodology and data sources.

By the end of this program, you will have completed a real-world artifact that demonstrates your competency to potential employers — not a quiz score, not a participation certificate. Proof of execution.

Need Any Help?

Talk to our advisors directly on WhatsApp.

Chat Now

Course Overview

Aggregate safety reporting is one of the most strategically important functions in pharmacovigilance — and one of the most technically demanding. Every pharmaceutical company with a marketed product must submit Periodic Safety Update Reports to regulatory authorities on a defined schedule, providing a comprehensive cumulative analysis of the drug's benefit-risk profile based on all available safety data. Development Safety Update Reports are required annually for all drugs in clinical development. Missing these submissions, or submitting reports that fail regulatory quality standards, triggers inspection findings, licence conditions, and in serious cases, market withdrawal proceedings. The professionals who build these reports carry significant regulatory responsibility.

This program builds the complete PSUR and DSUR competency stack from the ground up. You begin with the regulatory and documentation foundations — global regulatory bodies, GVP requirements, adverse event classification, and MedDRA coding — before moving into the ICSR-level data that feeds aggregate reports. From there you progress into the aggregate reporting workflow itself: PSUR architecture and ICH E2C(R2) requirements, DSUR structure and clinical development timelines, data aggregation methodology, line listing and summary tabulation construction, AI-assisted drafting workflows, benefit-risk evaluation frameworks, quality review processes, and regulatory submission procedures. MedDRA is trained as an integrated competency — coding accuracy, version management, and error resolution are embedded throughout because aggregate report integrity depends entirely on the quality of the underlying case coding.

By the end you carry a complete PSUR and DSUR reporting portfolio — compiled data, line listings, drafted report sections, quality documentation, and regulatory submission records — advisor-reviewed and published to your professional profile. In a function where documented execution capability is rare and consistently in demand, that portfolio is a direct hiring advantage.

Why This Over Everything Else

PSUR and DSUR reporting is taught in most pharmacovigilance training programs as a theory module — here is what a PSUR is, here is the ICH E2C(R2) structure, here are the regulatory timelines. None of that prepares you to sit down with a cumulative safety dataset, aggregate it correctly, build the line listings, draft the benefit-risk section, and submit a report that passes regulatory scrutiny. This program makes you do exactly that — inside a simulation that mirrors the real aggregate reporting environment, with AI tools integrated the way modern PV operations actually use them. You leave with a drafted report and a portfolio, not a definition.

What You'll Actually Learn

Curated Industry Competencies

  • Global PV Regulatory Bodies — FDA, EMA, PMDA, CDSCO and their aggregate reporting mandates
  • Adverse Event, SAE, and ADR Classification — regulatory definitions underpinning aggregate data
  • Good Pharmacovigilance Practices — GVP Module VII: Periodic Safety Update Report requirements
  • Introduction to MedDRA — dictionary structure and aggregate reporting application
  • Pharmacovigilance Documentation Essentials — data standards and audit trail requirements for aggregate reports
  • ICSR Overview and Structure — case-level data feeding aggregate safety analysis
  • Source Document Review — clinical data extraction and verification for aggregate datasets
  • Adverse Event Causality Assessment — evaluating causality across case series for aggregate analysis
  • MedDRA Coding for ICSRs — coding accuracy as the foundation of aggregate report integrity
  • ICSR Quality Checks — case-level data quality as a prerequisite for aggregate reporting
  • PSUR Overview and Requirements — ICH E2C(R2) structure, content, and regulatory mandates
  • DSUR Basics and Timelines — ICH E2F requirements, annual reporting obligations, and clinical development context
  • Data Aggregation for Safety Reports — methodology for compiling cumulative adverse event datasets
  • AI-Assisted PSUR Drafting — machine learning tools for section generation, data summarisation, and quality validation
  • Line Listings and Summary Tabulations — construction, formatting, and regulatory standards
  • PSUR Quality Checks — ICH E2C(R2) completeness criteria and regulatory submission readiness
  • DSUR Case Study Analysis — applying aggregate analysis methodology to clinical development safety data
  • Regulatory Submission of Aggregate Reports — submission procedures for FDA, EMA, and global agencies
  • Handling PSUR and DSUR Queries — responding to regulatory authority requests for clarification or additional data
  • MedDRA Hierarchy Architecture — five-level coding structure and aggregate reporting implications
  • LLT, PT, and SOC Coding — accurate term selection as aggregate data foundation
  • Coding Accuracy and Quality Controls — error identification and correction within aggregate datasets
  • Coding Error Resolution — correcting MedDRA discrepancies before aggregate data lock
  • MedDRA Version Updates — managing dictionary transitions across multi-year safety reporting periods

Systems You'll Use

Enterprise Software & Digital Workflows

Training includes hands-on work with the same tools, data standards, and regulatory frameworks used in real aggregate safety reporting operations globally.

  • PSUR and DSUR drafting templates aligned to ICH E2C(R2) and E2F standards
  • Cumulative adverse event dataset compilation and aggregation tools
  • Line listing and summary tabulation construction environments
  • MedDRA terminology browser — hierarchy navigation and coding verification for aggregate datasets
  • AI-assisted PSUR drafting and section generation tools
  • NLP-based data summarisation and benefit-risk evaluation support systems
  • Oracle Argus Safety — cumulative data extraction and aggregate reporting workflow integration
  • E2B(R3) case data reconciliation for aggregate dataset completeness
  • WHO VigiBase and FDA FAERS reference interfaces for cumulative signal context
  • Regulatory submission portals and electronic filing frameworks for FDA and EMA
  • PSUR and DSUR quality review checklists and sign-off documentation systems
  • Regulatory query management and response documentation workflows
AI tools are used as productivity multipliers, not replacements for professional judgment. This mirrors how modern drug safety teams actually operate.

Career Outcomes

Professional Roles & Impact

  • Aggregate Reporting Specialist
  • PSUR/DSUR Writer
  • Pharmacovigilance Medical Writer
  • Regulatory Safety Scientist
  • Periodic Reporting Associate
  • Drug Safety Scientist
  • Benefit-Risk Assessment Specialist
  • PV Regulatory Affairs Associate
  • Clinical Safety Analyst
  • Global Safety Reporting Coordinator

Average starting salary (India): ₹5–11 LPA

Global range: $55K–$95K USD

Aggregate safety reporting sits at the senior end of the pharmacovigilance function — above case processing, requiring both technical data competency and the regulatory judgement to evaluate a product's cumulative benefit-risk profile. Professionals with documented PSUR and DSUR drafting experience are among the most consistently sought-after specialists in the drug safety job market, particularly at pharmaceutical companies managing large marketed portfolios and CROs contracted to manage aggregate reporting obligations for global clients. AI-assisted reporting proficiency is an increasingly specified requirement at the top employers in this space.

Who This Program Is For

Eligibility & Background

  • Pharm.D
  • Pharm.D (PB)
  • B.Pharm
  • M.Pharm
  • MBBS
  • MD
  • BDS
  • MDS
  • BHMS
  • BAMS
  • BUMS
  • BSMS
  • B.Sc Nursing
  • M.Sc Nursing
  • B.Sc Life Sciences
  • B.Sc Biomedical Sciences
  • B.Sc Biotechnology
  • M.Sc Biotechnology
  • PG Diploma in Pharmacovigilance
  • PhD Pharmacology

Enrollment & Format

Format: Self-paced sprint with structured case milestones. Start: Within 24 hours of enrollment — rolling access. Completion: 7–9 days recommended. Access does not expire.

What Happens After You Enroll

Step-by-Step Process

1

Instant access to the ΩMEGA simulation environment and aggregate reporting workbench

2

Onboarding brief + first cumulative safety dataset assigned within 24 hours

3

Work through PSUR and DSUR drafting scenarios of escalating regulatory complexity

4

Submit your complete PSUR/DSUR Reporting Portfolio for Advisor review

5

Receive your verified digital credential upon sign-off

6

Portfolio artifact published automatically via AURIX

7

LinkedIn-ready certificate with one-click integration

LEARNING PATHWAY

FAQS

Is this Pharmacovigilance certification valid for global roles?
Yes. Our PV simulations (ICSR, MedDRA, Aggregate Reports) strictly adhere to E2B(R3) standards and ICH-GCP guidelines followed by the FDA, EMA, and PVPI. It is designed for professionals targeting global pharmacovigilance operations.
Are PSUR and DSUR reports generated using automated line listings?
Yes. The reporting certification focuses on drafting complete PSUR/DSUR dossiers using automated line listings for aggregate safety reporting.
What is a PSUR and why is it required by regulatory authorities?
A Periodic Safety Update Report is a comprehensive regulatory document that pharmaceutical companies must submit to health authorities at defined intervals throughout a drug's marketed lifecycle, providing a cumulative analysis of the product's global safety experience and an updated evaluation of its benefit-risk profile. PSURs are required under ICH E2C(R2) guidelines and are mandated by the EMA, FDA, PMDA, and most national regulatory agencies globally. They represent the primary mechanism through which regulators assess whether a marketed drug's safety profile has changed since approval and whether any regulatory action — label update, risk minimisation measure, or market withdrawal — is warranted.
What is the difference between a PSUR and a DSUR?
A PSUR — Periodic Safety Update Report — covers the post-approval safety experience of a marketed medicinal product, compiled at defined intervals based on the International Birth Date of the product. A DSUR — Development Safety Update Report — covers the safety experience of a drug that is still in clinical development, submitted annually to all regulatory authorities where clinical trials are ongoing. Both reports aggregate safety data across a defined reporting period and evaluate benefit-risk, but they differ in their regulatory framework — PSUR follows ICH E2C(R2), DSUR follows ICH E2F — and in the data sources and clinical context they draw on. This program trains both as integrated components of the aggregate reporting function.
What is ICH E2C(R2) and how does it govern PSUR reporting?
ICH E2C(R2) is the International Council for Harmonisation guideline that defines the structure, content, and format requirements for Periodic Safety Update Reports globally. It specifies the sections a PSUR must contain — executive summary, worldwide marketing authorisation status, cumulative exposure data, individual case narratives, signal evaluation, benefit-risk analysis, and conclusions — and sets the standards for each. Regulatory authorities in the EU, US, Japan, and all ICH member countries align their PSUR requirements to E2C(R2), making it the single most important document governing aggregate safety reporting practice.
Who should take the PSUR & DSUR Reporting Certification?
This program is designed for pharmacovigilance professionals who want to move into or advance within aggregate safety reporting — one of the most senior and well-compensated functions in drug safety. It is relevant for drug safety associates looking to progress beyond case processing, medical writers moving into regulatory PV writing, and regulatory affairs professionals expanding into safety reporting. Life sciences graduates entering the field who want to target senior-track PV roles from the outset will also find this program a highly strategic credential.
What are line listings and summary tabulations in aggregate safety reporting?
Line listings are tabular presentations of individual adverse event cases included in a PSUR or DSUR — each row represents one case and each column captures key case variables including patient demographics, suspect drug, adverse event term, seriousness, outcome, and causality assessment. Summary tabulations aggregate the line listing data into counts by system organ class, event term, seriousness, and outcome — providing the statistical overview of the product's cumulative adverse event profile. Both are mandatory components of a regulatory-standard PSUR and both must be built from accurately coded, quality-checked ICSR data. This program trains their construction as a hands-on simulation exercise.
How is AI being used in PSUR drafting?
AI tools are being deployed across the PSUR drafting workflow in several high-value ways. Natural language processing tools can summarise large volumes of ICSR narrative data into concise case series descriptions. Machine learning algorithms can flag inconsistencies between line listing data and narrative content. AI-assisted drafting platforms can generate initial section text — exposure data summaries, signal evaluation narratives, benefit-risk frameworks — which human medical writers then validate and refine. In high-volume aggregate reporting environments managing multiple PSURs simultaneously, these tools reduce drafting time significantly while maintaining the regulatory quality standard that submissions require. This program trains AI-assisted drafting as a core operational competency, not a theoretical add-ons.
What regulatory agencies receive PSURs and how are they submitted?
PSURs are submitted to all regulatory authorities in markets where the product holds a marketing authorisation. In the EU, PSURs are submitted to the EMA via the EU single assessment procedure for centrally authorised products, or directly to national competent authorities for nationally authorised products. In the US, FDA requires equivalent periodic safety reporting under 21 CFR Part 314. Japan's PMDA has its own periodic reporting requirements aligned to ICH E2C(R2). India's CDSCO requires PSUR submission under Schedule Y of the Drugs and Cosmetics Rules. This program trains regulatory submission procedures across all major agencies as part of the complete aggregate reporting workflow.
How does MedDRA coding quality affect PSUR integrity?
PSUR integrity is entirely dependent on the accuracy of the MedDRA coding in the underlying ICSR dataset. Line listings are sorted and presented by MedDRA System Organ Class and Preferred Term — if cases are miscoded, the aggregate data is wrong, the line listings are wrong, and the benefit-risk analysis is built on flawed foundations. Regulators review MedDRA coding consistency during PSUR assessments and inspection activities. This is why this program trains MedDRA coding accuracy, version management, and error resolution as embedded competencies within the aggregate reporting curriculum rather than treating them as separate prerequisites.
What happens when a regulatory authority raises a query on a submitted PSUR?
Regulatory queries on submitted PSURs — requests for clarification, additional data, or justification of specific benefit-risk conclusions — are a routine part of the aggregate reporting process, particularly for products under enhanced EU monitoring or those with emerging safety signals. Responding requires clear understanding of the original data, the ability to pull additional case analysis on short timelines, and the regulatory writing skill to address the query precisely without generating additional concern. This program trains PSUR and DSUR query handling as a simulation module — you receive a regulatory query on your submitted report and build the formal response with full documentation.
What is the career progression from PSUR reporting into more senior PV roles?
PSUR and DSUR reporting is one of the clearest pathways into the senior tier of pharmacovigilance. From aggregate reporting specialist the natural progression moves into signal management and benefit-risk assessment — roles that require the same cumulative safety data fluency but apply it to ongoing surveillance rather than periodic reporting. From there the path leads to PV medical director, regulatory safety strategy, and global pharmacovigilance lead positions at pharmaceutical companies. In the CRO sector, senior aggregate reporting specialists frequently move into account management and client-facing safety strategy roles. The combination of data competency, regulatory knowledge, and writing capability that PSUR reporting develops is foundational to every senior PV career trajectory.

Ready to Specialize in Simulation?

Upgrade to our 3-Month Pro Training programs for deep clinical immersion.

Explore Pro TrainingTalk to our Advisor